Alliancebernstein L.P. lowered its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 5.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,600 shares of the biotechnology company’s stock after selling 1,800 shares during the period. Alliancebernstein L.P. owned 0.08% of Seres Therapeutics worth $367,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in MCRB. American International Group Inc. raised its stake in shares of Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after buying an additional 727 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock worth $4,172,000 after buying an additional 50,860 shares during the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Seres Therapeutics by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after buying an additional 279 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of Seres Therapeutics during the first quarter worth $447,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of Seres Therapeutics during the first quarter worth $136,000. Institutional investors own 75.31% of the company’s stock.

Seres Therapeutics, Inc. (NASDAQ:MCRB) traded up 2.30% on Friday, reaching $13.77. 97,984 shares of the company’s stock were exchanged. Seres Therapeutics, Inc. has a one year low of $8.85 and a one year high of $15.09. The firm has a 50 day moving average of $12.55 and a 200-day moving average of $10.69. The stock’s market cap is $557.85 million.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The company had revenue of $3 million during the quarter, compared to analyst estimates of $3 million. During the same period in the previous year, the company earned ($0.70) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. Equities research analysts forecast that Seres Therapeutics, Inc. will post ($2.48) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://theolympiareport.com/2017/08/12/seres-therapeutics-inc-mcrb-shares-sold-by-alliancebernstein-l-p.html.

A number of equities research analysts recently weighed in on the stock. BidaskClub lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Zacks Investment Research lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Canaccord Genuity set a $20.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $17.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.